Full Year Report incl. Q4 2017
Strengthened financial position and continued profitability Financial overview Q4 2017 · Total net revenues SEK 191.0 million (184.7) · Zubsolv® US net revenue SEK 126.5 million (128.2). In local currency a growth of 7.2 percent. · EBIT SEK 30.1 million (33.2) · EBITDA SEK 35.3 million (44.1) · Earnings per share, before and after dilution, SEK 0.77/0.77 (0.97/0.96) · Cash flow from operating activities SEK -23.0 million (71.4) · Cash and cash equivalents SEK 327.9 million (282.4) Financial overview Full Year 2017 · Total net revenues SEK 643.7 million (